25I-NBOH (NBOH-2CI, Cimbi-27, 2-C-I-NBOH) is a derivative of the phenethylamine derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. It acts as a potent agonist for the 5HT2A receptor, with a Ki of 0.061nM at the human 5HT2A receptor, similar to the better-known compound 25I-NBOMe, making it some twelve times the potency of 2C-I itself. In vitro tests showed this compound acted as an agonist but animal studies have not been reported. While the N-benzyl derivatives of 2C-I were significantly increased in binding activity to 5HT2A receptor fragments, compared to 2C-I, the N-benzyl derivatives of DOI were less active, compared to DOI.
my contact infomation is:
Notice: This product is only suitable for laboratory use, or the use of animals. It can not be used directly on the human body